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The present study assessed the suitability of the streptozotocin-treated diabetic rat as a model for the study
of diabetes-impaired wound healing. The distribution of three antibiotics, ampicillin, benzylpenicillin, and
flucloxacillin, in wound and adjacent tissue sites on the abdomens and legs of normal and diabetic rats was
determined 30 min after intravenous administration of a single bolus containing 50 mg of all three antibiotics
per kg of body weight. Tissue/plasma ratios showed that antibiotic tissue penetration appeared to be related
to protein binding. The treatment of wound sites with vasodilators (1% solution) to increase local blood flow
and antibiotic delivery to the site was then determined and appeared to be more effective with endothelium-
independent sodium nitroprusside than with endothelium-dependent acetylcholine in diabetic rats. These
results suggest that coadministration of topical vasodilators to wound sites in neuropathic diabetic patients
undergoing antibiotic therapy for infected ulcers could increase antibiotic delivery to wound tissue sites.
Diabetes mellitus is traditionally associated with an in-
creased risk of complications and infections during wound
healing. Diabetics are prone to peripheral vascular disease and
peripheral neuropathy, particularly in the lower extremities,
which result in loss of sensation and reduced ability to detect
injury or developing ulcers. Reduced skin blood flow in the
lower extremities in diabetics has been attributed to defects in
the function of sensory nerve fibers and subsequent control of
the microvasculature compared with normal subjects or con-
trols in both diabetic patients and streptozotocin (STZ)-
treated rats (4, 11, 18, 24, 25, 27, 38, 47). Studies examining the
effect of various endothelium-dependent and -independent va-
sodilators have shown that although endothelial function is
impaired in diabetes, microvascular smooth muscle responds
to normal stimuli (45). It is suggested that subsequent reduced
neuronal blood flow induces the observed nerve function def-
icits. Robertson et al. (33) demonstrated that skin blood flow
and nerve conduction velocity in STZ-treated rats at rest were
significantly below those of controls, though muscle blood flow
appeared normal. They were subsequently able to show that
treatment with nifedipine, a vasodilator that acts directly on
smooth muscle, could prevent nerve conduction deficits in ex-
perimental diabetes. Reduced axon reflex vasodilatation in
patients with diabetic neuropathy has been attributed to loss of
afferent c-fiber nerve function (20, 29). Stimulation of musca-
rinic receptors on endothelial cells causes the release of endo-
thelium-derived relaxing factors (13), and studies on vascular
smooth muscle have identified nitric oxide as the major endo-
thelium-derived physiologic relaxing agent (28). Westerman et
al. (45) examined vasodilator responses in the skin of diabetic
patients in response to iontophoresis of the 1% acetylcholine
(ACh) (endothelium-dependent) and 1% sodium nitrite (en-
dothelium-independent) vasodilator agents. The studies re-
vealed reduced vasodilator responses to ACh but not to so-
dium nitrite in patients with diabetic neuropathy compared
with normal controls, suggesting that endothelial function in
blood vessels is impaired but vascular smooth muscle appears
to respond normally. The loss of neuronal function leaves the
diabetic unable to detect soft tissue injury in the lower leg and
feet and unable to mount any kind of adequate inflammatory
response to that injury and, thus, susceptible to aggressive
bacterial infection and tissue damage which can be potentially
life threatening if not treated effectively.
Clinical reports have confirmed that deep cultures from di-
abetic soft tissue infections grow multiple organisms and so
aggressive therapy with a regimen of broad-spectrum antibiot-
ics is always recommended (23, 35–37). Present treatment of
these infections consists of various surgical procedures ranging
from debridement to amputation in combination with antibi-
otic therapy. Initial antibiotic treatment must be bactericidal
and most commonly consists of an aminoglycoside employed
against aerobic bacteria with a b-lactamase-resistant penicillin
to cover enterococci and anaerobic bacteria. In recent years a
number of studies have highlighted the problem of relying on
serum antibiotic concentrations as an indication of therapeutic
levels in soft tissue sites. Seabrook et al. (36) demonstrated in
diabetic patients undergoing foot surgery that adequate serum
levels of a number of antibiotics were not reflected in infected
tissue samples. Storm et al. (41) also showed that following
oral administration of cefuroxime in 12 patients, although ad-
equate serum levels were achieved, no antibiotic could be
found in wound exudate samples. The inability of systemic
antibiotics to penetrate adequately into superficial peripheral
wounds and ulcers of diabetics is not surprising considering the
numerous reports of reduced blood flow to these regions and
the reduced inflammatory and/or immune responses of dia-
betic patients necessary to overcome continued tissue infesta-
tion by bacteria.
The aim of the present study was to take advantage of the
impaired microvascular control demonstrated in STZ-treated
diabetic rats to create a model of excisional wound healing in
which the penetration of a number of commonly used b-lactam
antibiotics could be measured. The literature shows that a di-
rect comparison of wound contracture rates with those in non-
diabetic animals has never been published using this model. A
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second aim was to determine the effect of stimulation of dila-
tion of the local microvasculature on antibiotic penetration
into wound sites, on both the abdomen and hindleg, using an
endothelium-dependent (ACh) and -independent (sodium ni-
troprusside [SNP]) vasodilator (12) applied directly over the
granulating wound site. The hypothesis behind this study is
that if, as suggested in the literature, the smooth muscle of the
microvasculature of diabetics functions normally, then an en-
dothelium-independent vasodilator may cause dilation of ves-
sels in and around the wound site and increase the delivery of
systemically administered antibiotics simply because of the in-
creased perfusion of the area.
MATERIALS AND METHODS
Materials. Benzylpenicillin (BP), ampicillin (AMP), and flucloxacillin (FLU)
were a gift from the Commonwealth Serum Laboratories (Parkville, Victoria,
Australia); cefotaxime, dicloxacillin, and STZ were purchased from Sigma
Chemical Co. (Castle Hill, New South Wales, Australia). Sodium heptane sul-
fonate was purchased from Biolab Pty (Clayton, Victoria, Australia), acetonitrile
(high-performance liquid chromatography [HPLC] grade) was obtained from
Mallinckrodt (Clayton, Victoria, Australia), and water was purified and deion-
ized with a Waters Milli-Q unit (Millipore Waters, Brisbane, Queensland, Aus-
tralia).
Male Wistar rats (359 6 89g) were used throughout the studies. The animals
were housed under standard laboratory conditions (20.0 6 0.58C, 55% to 75%
humidity, pellet food and water ad libitum).
Methods. (i) HPLC method for analysis of antibiotics. HPLC assays were
developed and validated to allow the quantitation of AMP, BP, and FLU in
biological samples. A model 250 isocratic pump, LC90 BIO, variable wavelength
UV detector with a model 1020 computing integrator (Perkin-Elmer, Glen Waver-
ley, Victoria, Australia) was employed for the assay of all antibiotics. Samples
were introduced onto an Alltima C18 column (250 by 4.6 mm; inner diameter, 5
mm) (Alltech Assoc., Brisbane, Queensland, Australia) with a Newguard C18
guard column (15 by 3.2 mm; particle size, 7 mm) (Alltech Assoc.) by using a
Shimadzu SIL 9A auto-injector. The mobile phase for analysis of AMP consisted
of 10:90 (vol/vol) acetonitrile:0.05 M sodium dihydrogen phosphate (pH 5.0) at
a flow rate of 1 ml min21, with detection effected at 215 nm with cefotaxime as
the internal standard. The mobile phase for co-analysis of BP and FLU consisted
of 30:70 acetonitrile:0.05 M sodium dihydrogen phosphate (pH 5.0) at a flow rate
of 1 ml min21, with detection effected at 214 nm with dicloxacillin as the internal
standard.
Total antibiotic concentrations in urine and plasma were determined by plac-
ing an aliquot of plasma (50 ml) or urine (100 ml) into an Eppendorf tube with
an equal volume of internal standard solution and then adding acetonitrile to
precipitate protein (100 ml to plasma and 200 ml to urine). After vortexing for
30 s, samples were centrifuged at 5,000 3 g for 15 min, and the supernatant was
removed for analysis.
Tissue samples were weighed into Eppendorf tubes, chopped finely with dis-
section scissors, and suspended in 200 ml of water. One hundred microliters of
the appropriate internal standard (100 mg ml21) was added, and the samples
were sonicated on ice by using a 3 mm ultrasonic microtip (Sonics and Materials
Inc., Danbury, Conn.) for 60 s. Two hundred microliters of acetonitrile was
added to precipitate protein and the samples were vortex mixed for 30 s and then
centrifuged at 10,000 3 g for 15 min in a bench top centrifuge. The supernatant
was then assayed for total antibiotic. Recovery of antibiotic was determined in
spiked homogenates at concentrations of 1 to 30 ml ml21.
(ii) Rat wound model. Rats were rendered diabetic by the injection of STZ (60
mg/kg of body weight intraperitoneally), prepared immediately prior to injec-
tion, in sodium citrate buffer (0.15 M NaCl adjusted to pH 4.5 with 0.15 M
citrate). Controls received vehicle alone. After 6 weeks, animals with a blood
glucose consistently above 350 mg/dl (pre-injection blood glucose, 120.95 6 13.5
mg/dl), measured with Accutrend glucose test sticks (code 208) and meter
(Boehringer Mannheim Australia Pty, Castle Hill, New South Wales, Australia),
were classed as diabetic.
Two excisional wounds (15 by 15 mm) were created, either one on each side
of the abdomen or one on each thigh, 7 days prior to antibiotic distribution
studies and 5 weeks after STZ or vehicle treatment by using previously described
methods (7). Briefly, rats were anesthetized with sodium pentobarbitone (60 mg
of drug per kg, intraperitoneally), and hair from the wound area was removed
with electric clippers and Nair depilatory cream before swabbing the area with
alcoholic chlorhexidine solution and drying the area. Wound areas were marked
by using a template, and the area of skin confined by the markings was removed
to the depth of the muscle fascia by using dissecting scissors and forceps. The
wounds were immediately dressed with Opsite semipermeable transparent self-
adhesive dressings, secured at the corners with Supaglue adhesive. Animals were
housed singly and for the first 48 h postwounding the dressings were left undis-
turbed, after which they were removed and the wounds were exposed to the air.
Preliminary studies to assess the effect of diabetes on wound contraction rates
were performed by monitoring wound areas in a group of six diabetic and four
normal rats by repeating daily the tracing of wound sizes with the animals held
in a standard crouching position (7). Wound tracings were photocopied (normal
size) and computer digitized to give a measure of wound area.
Statistical analysis of the healing rates of the two groups was performed by
using analysis of variance to compare the mean constants by which each animal’s
wound decreased in size. A Kaplan Meir survival analysis statistic was also
performed at 90% healing with the log rank test.
(iii) Antibiotic distribution studies.On the day of the study, 7 days postwound-
ing, animals were anesthetized with sodium pentobarbitone (60 mg/kg, intraperi-
toneally), and the right jugular vein was cannulated with PE50 tubing (Clay-
Adams, Parsippany, N.J.) flushed with heparinized saline. A blood sample was
withdrawn to act as a blank for these animals, and the animals left for at least 10
to 15 min to stabilize. After this time filter paper discs soaked in either saline
(control) or saline containing freshly prepared 1% ACh or 1% SNP were placed
over the two wound sites and covered with Opsite dressings. After 10 min 50 mg
were of each of the antibiotics (AMP, BP, and FLU) per kg was introduced
together as a single bolus (,0.5 ml) in saline warmed to 378C into the jugular
cannula; this was followed by 0.2 ml of warmed saline to flush the cannula.
Antibiotics were allowed to circulate for 30 min, after which time a blood sample
was withdrawn from the tail vein and the animals were sacrificed by the intro-
duction of 1 ml of concentrated potassium chloride into the jugular cannula.
Dressings and filter paper discs were removed from the wounds and discarded,
and then wound tissues (granulation tissue, subcutaneous tissue skin and muscle
tissue from below the granulation tissue, surrounding intact skin, and adjacent
tissue below the intact skin) were dissected into sterile Eppendorf tubes on ice
for HPLC determination of total antibiotic concentrations. The abdomen was
then opened and bladder contents were completely aspirated into preweighed
Eppendorf tubes on ice for determination of urinary excretion of each of the
antibiotics.
RESULTS
HPLC assay. Because of differing retention characteristics,
the three antibiotics (AMP, BP, and FLU) could not be ana-
lyzed simultaneously by using one isocratic method. Two sep-
arate methods were therefore developed with similar mobile
phases, one for BP and FLU and a second for AMP. Typical
chromatograms of the assays are shown in Fig. 1. The retention
times of BP, FLU, and the internal standard dicloxacillin were
6.4, 11.3, and 13.9 min, respectively. AMP and its internal
standard cefotaxime were eluted at 4.3 and 11.6 min, respec-
tively. Blank injections showed that peaks due to endogenous
material were well separated from analyte peaks (data not
shown). Detection at 215 nm as opposed to 254 nm allowed
greater sensitivity, and quantitation limits of each of the anti-
biotics in plasma were 0.5, 0.8, and 1.0 mg/ml for AMP, BP, and
FLU, respectively. The quantitation limits were 1.0 mg/ml in
urine and 2.5 mg/g in tissue for all three antibiotics. Over the
concentration range studied, the linearity of response was
found to be good for all solutes (r2 . 0.994 with negligible
intercept), and the mean recovery from tissue homogenates
was 87.7% 6 1.6%. The reproducibility of the assays and extrac-
tions was good on an inter- and intraday basis (CV[%], 7).
Rat wound healing model. Closure rates of the excisional
abdominal wounds (15 by 15 mm) in STZ-treated diabetic rats
were significantly slower than those in saline-treated nondia-
betic controls (analysis of variance, P , 0.005) (Fig. 2). A
statistical difference was also shown with the model-indepen-
dent Kaplan Meir survival analysis at 90% healing (P5 0.006).
The wound area-time profiles for both study groups follow an
exponential decline, as shown by the straight line semi-log plot
of Fig. 2, with retardation of closure in diabetic rats seen more
clearly after the first 6 to 7 days.
Antibiotic distribution. The highest plasma concentration at
the 30-min sampling point was seen with BP followed by AMP
and FLU (Table 1). Although there seemed to be a trend
towards higher plasma levels in normal rats, there was no
significant difference in plasma concentrations of individual
antibiotics between diabetic and normal rats or between ani-
mals treated with either of the vasodilators.
Total urinary excretion of individual antibiotics was signifi-
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cantly higher in diabetic rats compared with that in nondiabetic
controls (P , 0.05). However, the concentrations of antibiotic
per milliliter of urine formed (Table 1) were not significantly
different for individual antibiotics between diabetic and non-
diabetic groups. The highest urine levels for both diabetic and
nondiabetic rats were of AMP, which was followed by BP and
FLU. The concentrations of AMP, BP, and FLU recovered in
the urine represented only a very small fraction of the admin-
istered dose, approximately 0.02 and 0.004 for AMP, 0.01 and
0.002 for BP, and 0.005 and 0.001 for FLU in diabetic and
nondiabetic groups, respectively. There was no significant dif-
ference in the urine concentrations of antibiotics for diabetic
and nondiabetic rats between vasodilator treatment groups.
The highest tissue/plasma ratios were seen with AMP fol-
lowed by FLU and BP (Table 1). Tissue/plasma ratios of an-
tibiotics tended to be higher in abdominal than in peripheral
leg wound sites for both diabetic and nondiabetic animals (Fig.
3 and 4). Several of the leg tissues sampled contained no
detectable amounts of antibiotic, particularly for BP and FLU,
a trend which was much more obvious in ACh-treated animals
than in animals that received topical SNP.
The literature shows that AMP has the lowest protein bind-
ing capacity of the three antibiotics studied (3) (Table 1). Table
1 shows an estimate of the mean antibiotic tissue concentra-
tions derived from mean tissue/plasma ratios and mean plasma
concentrations, together with the approximate mean unbound
tissue concentrations calculated by using the published protein
binding figures. It can be seen that AMP has 40 and 140 times
the unbound tissue concentration of BP and FLU, respectively.
Statistical analysis of tissue/plasma ratios following vasodi-
lator treatment failed to show any level of significance, largely
because of the interanimal variability in tissue concentrations.
However, results are discussed concerning the general trends
seen in the changes in antibiotic tissue/plasma ratios in wound
versus contralateral sites and between diabetic and control
animals. Treatment of abdominal wound sites with ACh re-
sulted in only a slightly increased level of FLU in granulation
tissue over the level of FLU in the contralateral sites and BP in
the wound bed of diabetic rats (Fig. 3 and 4). No changes were
seen in the tissue/plasma ratios of AMP in abdominal sites in
either diabetic or nondiabetic rats (Fig. 3). In the leg wound
sites, ACh caused an increase in the tissue/plasma ratio of FLU
in wound subcutaneous tissue of diabetic and nondiabetic rats
in which low contralateral levels were detected (Fig. 4). No
obvious changes were seen in the levels of AMP and BP in
either diabetic or nondiabetic rats.
Trends towards higher tissue/plasma ratios of antibiotics fol-
lowing topical treatment of abdominal wounds with SNP, com-
pared with contralateral saline-treated sites, were seen in the
granulation and subcutaneous tissue of diabetic rats (Fig. 3).
SNP applied topically to abdominal wound sites in nondiabetic
rats appeared to have negligible effect on antibiotic concentra-
tions.
In leg wound sites, SNP increased the tissue/plasma ratio of
FLU in granulation tissue and the underlying muscle above
contralateral levels in diabetic rats, and to a lesser extent in
nondiabetic rats (Fig. 4). Variable results were seen in tissue/
FIG. 1. Typical chromatograms of BP FLU extracted from rat muscle with
dicloxacillin (DIC) as internal standard (A) and AMP extracted from rat muscle
with cefotaxime (CEF) as internal standard (B). Chromatographic conditions are
described in the text.
FIG. 2. Relationship between log wound area and day of healing of (15 by 15
mm) abdominal wounds in diabetic (E) (n5 6) and nondiabetic (F) (n5 4) rats.
Data are means 6 standard errors.
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plasma ratios of BP; however, increased wound subcutaneous
levels were evident following topical SNP treatment compared
with contralateral sites. No obvious changes were seen in BP
levels in nondiabetic rats (Fig. 4). Concentrations of AMP
between SNP-treated and contralateral leg wound sites ap-
peared similar in both diabetic and nondiabetic groups, al-
though the concentrations appeared slightly higher and more
variable than those for the ACh-treated group (Fig. 4).
DISCUSSION
The antibiotics chosen for the study, AMP, BP, and FLU,
are all semisynthetic penicillins which are often prescribed in
clinical practice for a variety of soft tissue infections. The
HPLC assays and sample extraction procedures developed for
AMP, BP, and FLU were shown to be accurate and precise
through validation experiments. Both methods utilized simple
sample preparation and provided a rapid method for the quan-
titation of antibiotics in plasma, urine, and tissue.
The rat model of excisional wound healing was based on a
previously validated model (7). The induction of diabetes with
STZ was chosen after an extensive review of diabetic rat mod-
els in the literature. The use of blood glucose above 350 mg/dl
to determine diabetes compares well with levels used in the
literature of 220 to 360 mg/dl (5, 21). For the present study, it
was important that the rat diabetic model chosen should reflect
the changes in skin blood flow and peripheral neuropathy
which contribute to the delayed wound healing responses in
diabetic patients (1, 2, 15, 26, 30, 32, 34, 43). Evidence in the
literature points to the suitability of the STZ-treated rat model
of diabetes as an experimental model of the human condition
also incorporating some of the secondary clinical complica-
tions seen in diabetic patients (4, 11, 18, 24, 25, 27, 33, 38, 47).
The significant reduction in wound contraction rates ob-
served in this study can be correlated to impaired wound heal-
ing seen in diabetic patients (1, 2, 15, 26, 30, 32, 34). The
differences in wound size between diabetic and nondiabetic
rats became more pronounced after the first 6 to 7 days, which
is consistent with reports of a prolonged inflammatory phase
and delayed wound granulation maturation and collagen ma-
trix deposition due to diabetes (10, 16, 17, 31). Statistical dif-
ference between the two groups was shown based on our pre-
viously published methods (7).
The penetration of systemically administered antibiotics into
soft tissue sites is crucial to the success of diabetic ulcer anti-
biotic therapy. Over recent years it has been highlighted that
antibiotic plasma concentrations cannot always be accepted as
a reflection of tissue concentrations, particularly at wound sites
(36, 41). Contradictory results have been published by Duck-
worth et al. (9), who found good therapeutic tissue concentra-
tions of clindamycin in four of four diabetic patients treated for
foot infections, and Seabrook (36), who found no detectable
levels in similar patients using the same dose. It is obvious from
these findings that a problem of sufficient antibiotic coverage in
tissue sites does exist in many diabetic patients. Variation in
the results of previous studies could have been expected, since
the authors had little control over the exact tissue sampling
points following antibiotic administration prior to surgery, with
tissue concentrations presented for individual patients differ-
ing in antibiotic administration time by as much as 1 to 4 h by
Storm et al. (41), 4.5 to 6.5 h by Duckworth et al. (9), and
undefined by Seabrook et al. (36). The present study is effec-
tively a single-dose study and the results are limited to this
situation, with further studies being needed to assess the ap-
plicability of these findings to chronic antibiotic treatment.
Some of the error introduced into previously reported results
was eliminated by examining all antibiotic concentrations at a
single time point after administration. It is recognized that the
distribution phase of each of the chosen antibiotics would
differ slightly, and therefore the design of the present study had
to enable comparison of the relative distribution between di-
abetic and nondiabetic wound sites and the effects of vasodi-
lator treatment irrespective of antibiotic time course. This was
achieved by the use of sampling periods of exactly 30 min,
when the stage of distribution should be similar in each animal,
allowing them to act as their own controls.
Observation of the highest tissue/plasma ratios for AMP is
consistent with previous studies (36) and reports of a linear
relationship between protein binding and the extravascular
penetration of antibiotics (39, 46). Differences in urinary ex-
cretion of the antibiotics in the study were not expected to have
a significant effect on the tissue distribution of the antibiotics
between the groups, since the excreted amount represented
only a small fraction (0.001 to 0.02) of the administered dose.
Studies of the influence of protein binding on the penetration
of antibiotics from vasculature into tissue spaces have gener-
ated conflicting data. Waterman et al. (44) found no relation-
ship between the protein binding properties of cephaloridine
and cefazolin and penetration into polypropylene balls in dogs.
Similarly, Gerding and Hall (14) saw little difference in the
penetration of fairly highly bound cephalosporins compared
with poorly bound aminoglycosides into peritoneal fluid of
rabbits. However, relationships between protein binding and
extravascular penetration of antibiotics have been shown with
AMP and cloxacillin into human synovial fluid (19) and with
b-lactams into human blister fluid (39, 42, 46). The clinical
importance of protein binding of antibiotics, however, remains
controversial. The protein most often involved in interactions
with antibiotics is albumin, and the interactions are generally
rapidly reversible and drug molecules constantly undergo bind-
ing and release, maintaining an equilibrium between bound
and free fractions (6). Consequently, a free fraction of even
highly bound antibiotics will be maintained in the plasma by
being constantly replaced as the antibiotic enters extravascular
spaces. The most important clinical significance of antibiotic
protein binding is that the bound fraction does not possess any
antimicrobial activity, and thus high tissue concentrations of a
highly bound antibiotic may possess only low antimicrobial
activity. The results of the present study favor a relationship
between unbound concentration and tissue penetration; how-
ever, other factors, such as lipophilicity, need to be further
addressed to properly predict tissue penetration capabilities.
The most suitable antibiotic for tissue penetration at the
time point used in the present study was AMP. Differences in
the distribution phases of the antibiotics at the 30 min time
TABLE 1. Plasma, tissue, and urine distribution
of AMP, BP, and FLUa
Anti-
biotic
Concn
Tissue/
plasma
ratiob
Protein
binding
(%)c
Plasma
(mg/ml)
Tissue
(mg/g)
Unbound
tissue
(mg/g)
Urine
(mg/ml)
AMP 30.4 6 5.9 173.5 142.3 168.2 6 15.7 5.70 6 0.5 18
BP 81.9 6 16.9 10.7 3.7 64.3 6 3.8 0.13 6 0.2 65
FLU 13.1 6 3.2 14.8 1.0 37.6 6 5.0 1.13 6 0.2 93
a Data (except those for protein binding) are means across all groups (n5 24).
Standard errors are indicated for antibiotic distributions in plasma and urine and
for tissue/plasma ratios.
b Data are means across all groups and tissues sampled.
c Data are from reference 3.
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12 12
point were not thought to be responsible for the observed
results. For example, the half-lives and volumes of distribution
of AMP and BP are reputedly similar (1.0 and 0.7 h, and 0.3
and 0.4 liter/kg respectively) (3). The low tissue/plasma ratios
of BP but high plasma concentrations of BP suggest that an-
tibiotics with similar physicochemical properties, unless they
are extremely potent, would be unsuitable for the systemic
treatment of soft tissue infections, particularly as a number of
the tissues sampled in the present study showed no detectable
concentrations of BP (Fig. 3 and 4). These observations imply
that, overall, BP represents a structure with little tissue-pene-
trating power but a reasonable ability to maintain high plasma
levels while undergoing moderate excretion into the urine in
an unchanged form. The 10 times higher mean tissue/plasma
ratios of FLU over BP are confounded by the high protein
binding of FLU, meaning that the active unbound fraction in
the tissues is much lower than anticipated (Table 1).
The low plasma and urine concentrations of FLU initially
suggested that this antibiotic could have the highest fraction of
dose distributed into body tissue compartments; however, re-
sults from the present study show that in the tissues sampled,
this did not appear to be the case. If FLU was partitioning in
FIG. 3. Abdominal tissue/plasma ratios of AMP, BP, and FLU in ACh- or SNP-treated ( , diabetic; s, nondiabetic) and contralateral ( , diabetic;h, nondiabetic)
wound sites. Data are means 6 standard errors (n 5 3).
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the tissue spaces, suggested by its low plasma concentration,
tissue/plasma ratios would be expected to be much higher.
FLU is reported to have a longer half-life (1.5 h) and lower
volume of distribution (0.15 liter/kg) than AMP or BP (3), and
therefore, would have been expected to be present in the
plasma in concentrations higher than those found in the
present study. Other possibilities for the distribution of FLU
include accumulation in body compartments not sampled or
presence in the samples in a metabolized form not detected by
our HPLC assay. A further study of the complete time course
of FLU distribution and elimination is needed to assess its
suitability for tissue penetration, though the present results
suggest that FLU may not be the antibiotic of choice for
peripheral soft tissue infections, as antibiotic cover does not
seem to be maximized in the tissue spaces.
Of the two vasodilators, SNP appeared to have the ability to
increase antibiotic tissue/plasma ratios in more of the tissue
sites studied compared with contralateral sites than was ob-
served with ACh. It was also noted that for the abdominal
wound sites, diabetic animals treated with SNP showed higher
FIG. 4. Leg tissue/plasma ratios of AMP, BP, and FLU in ACh- or SNP-treated ( , diabetic; s, nondiabetic) and contralateral ( , diabetic;h, nondiabetic) wound
sites. Data are means 6 standard errors (n 5 3).
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tissue/plasma ratios for BP and FLU than did normal rats
treated with SNP or either group treated with ACh (Fig. 3 and
4). This result could have occurred because of some systemic
absorption of SNP over the 30-min treatment period, resulting
in increased treated and contralateral levels of the dilator and
subsequently the antibiotics (Fig. 3E and F). The direct-acting
nature of SNP would be expected to cause an immediate va-
sodilatation in wound areas where endogenous mechanisms
had failed in diabetic animals, whereas in nondiabetic rats it
would be expected that vasodilatation in wound sites would
already be maximal.
The use of topical vasodilators to promote healing has been
attempted in the past. Lishner et al. (22) reported that 20 min
of daily soaking of debrided diabetic foot ulcers in a solution of
25% dimethylsulfoxide in saline resulted in increased healing
rates over controls. The mechanism behind this response, how-
ever, was attributed to a combination of effects, including in-
creased local vasodilatation, decreased thrombocyte aggrega-
tion, and increased oxygen diffusion (22). Our review of the
current literature has not shown any attempt to increase the
local concentration of systemically administered drugs by spe-
cific vasodilatation of the microvasculature in or around wound
sites. The doses of vasodilator chosen were based on the dose-
response studies of Westerman et al. (45), who iontophoresed
1% solutions of ACh (10 s) and sodium nitrite (20 s) through
intact skin of diabetics and normal patients and recorded
changes in microvascular vasodilatation. It has been demon-
strated by our group that iontophoresis effectively delivers
solutes through the skin at the same rate seen with passive
diffusion when the major barrier to transport, the epidermis, is
removed (8, 40). In the present study vasodilators were applied
directly to excisional wound sites, with no intact epidermis, and
so the doses applied reflected those delivered by iontophoresis
by Westerman et al. (45), but with a longer application period
to allow for hydration of, and absorption through, surface
granulation tissue.
In summary, the present study has shown that the STZ-
treated diabetic rat is a suitable model for the study of diabe-
tes-impaired wound healing. The distribution of AMP, BP, and
FLU into tissue spaces appears to be related to protein bind-
ing, with AMP showing the highest tissue/plasma ratios. The
treatment of wound sites with vasodilators to increase local
blood flow and antibiotic delivery to the site appears to be
more effective with endothelium-independent SNP than with
endothelium-dependent ACh in diabetic rats. These results
suggest that coadministration of topical vasodilators to wound
sites in neuropathic diabetic patients undergoing antibiotic
therapy for infected ulcers can increase antibiotic delivery to
wound tissue sites.
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